| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 0.92 [0.87, 0.96] | | < 1 | | 26% | 104 studies (104/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| death or transfer to ICU | 0.88 [0.73, 1.07] | | < 1 | | 32% | 9 studies (9/-) | 89.4 % | some concern | serious | moderate | crucial | - |
| deaths | 0.90 [0.87, 0.94] | | < 1 | | 19% | 219 studies (219/-) | 100.0 % | some concern | critical | moderate | crucial | 1 |
| deaths (time to event analysis only) | 0.85 [0.78, 0.93] | | < 1 | | 50% | 39 studies (39/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| clinical deterioration | 0.78 [0.68, 0.90] | | < 1 | | 40% | 42 studies (42/-) | 100.0 % | some concern | low | moderate | important | - |
| clinical improvement | 1.17 [1.09, 1.25] | | > 1 | | 47% | 58 studies (58/-) | 100.0 % | some concern | critical | moderate | important | - |
| clinical improvement (14-day) | 1.17 [1.03, 1.33] | | > 1 | | 47% | 29 studies (29/-) | 99.3 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.28 [1.12, 1.46] | | > 1 | | 41% | 22 studies (22/-) | 100.0 % | some concern | critical | moderate | important | - |
| clinical improvement (7-day) | 1.17 [1.00, 1.37] | | > 1 | | 49% | 19 studies (19/-) | 97.5 % | some concern | critical | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.14 [1.08, 1.22] | | > 1 | | 18% | 33 studies (33/-) | 100.0 % | some concern | critical | moderate | important | - |
| death or ventilation | 0.92 [0.88, 0.97] | | < 1 | | 53% | 40 studies (40/-) | 99.9 % | some concern | critical | moderate | important | - |
| hospital discharge | 1.04 [1.00, 1.08] | | > 1 | | 48% | 36 studies (36/-) | 97.5 % | some concern | critical | moderate | important | - |
| hospitalization | 0.67 [0.20, 2.17] | | < 1 | | 63% | 4 studies (4/-) | 74.9 % | low | not evaluable | high | important | - |
| mechanical ventilation | 0.88 [0.81, 0.95] | | < 1 | | 21% | 64 studies (64/-) | 99.9 % | some concern | critical | moderate | important | 1 |
| mechanical ventilation (time to event analysis only) | 0.79 [0.47, 1.33] | | < 1 | | 22% | 5 studies (5/-) | 81.2 % | some concern | serious | moderate | important | - |
| radiologic improvement (14-day) | 2.13 [1.30, 3.50] | | > 1 | | 21% | 6 studies (6/-) | 99.9 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.40 [0.02, 6.97] | | > 1 | | 77% | 3 studies (3/-) | 26.9 % | some concern | not evaluable | moderate | important | - |
| Recovery (time to event analysis only) | 1.02 [0.81, 1.28] | | > 1 | | 0% | 1 study (1/-) | 56.7 % | NA | not evaluable | | important | - |
| viral clearance | 1.60 [1.20, 2.13] | | > 1 | | 75% | 23 studies (23/-) | 99.9 % | some concern | critical | moderate | important | - |
| viral clearance (time to event analysis only) | 1.22 [0.91, 1.62] | | > 1 | | 67% | 9 studies (9/-) | 90.8 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 1.15 [0.61, 2.18] | | > 1 | | 91% | 16 studies (16/-) | 66.6 % | some concern | low | moderate | important | - |
| viral clearance by day 7 | 1.23 [1.00, 1.52] | | > 1 | | 63% | 17 studies (17/-) | 97.2 % | some concern | low | moderate | important | - |
| ICU admission | 0.81 [0.69, 0.95] | | < 1 | | 11% | 35 studies (35/-) | 99.5 % | some concern | low | moderate | non important | - |
| Major thrombotic events or death | 1.04 [0.80, 1.36] | | < 1 | | 0% | 1 study (1/-) | 38.7 % | NA | not evaluable | | non important | - |
| off oxygenation | 1.39 [0.29, 6.74] | | > 1 | | 70% | 3 studies (3/-) | 65.7 % | high | not evaluable | low | non important | - |
| recovery | 1.12 [1.01, 1.23] | | > 1 | | 33% | 14 studies (14/-) | 98.6 % | some concern | critical | moderate | non important | - |
safety endpoints 00 |
| AE leading to drug discontinuation | 2.43 [0.79, 7.45] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
| cardiac arrest | 1.92 [0.35, 10.49] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | important | - |
| composite safety outcome | 1.56 [0.78, 3.11] | | < 1 | | 0% | 1 study (1/-) | 10.3 % | NA | not evaluable | | important | - |
| related AE (TRAE) | 1.26 [0.14, 11.07] | | < 1 | | 0% | 2 studies (2/-) | 41.9 % | some concern | not evaluable | moderate | important | - |
| related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
| serious adverse events | 1.00 [0.89, 1.12] | | < 1 | | 14% | 50 studies (50/-) | 51.9 % | some concern | low | moderate | important | - |
| superinfection | 0.80 [0.50, 1.27] | | < 1 | | 61% | 5 studies (5/-) | 82.9 % | some concern | not evaluable | moderate | important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 1.48 [1.26, 1.76] | | < 1 | | 52% | 44 studies (44/-) | 0.0 % | some concern | critical | moderate | non important | - |
| arrhythmia | 0.91 [0.72, 1.15] | | < 1 | | 0% | 3 studies (3/-) | 78.1 % | some concern | not evaluable | moderate | non important | - |
| deep vein thrombosis | 0.62 [0.23, 1.64] | | < 1 | | 0% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
| elevated liver enzymes | 0.95 [0.29, 3.10] | | < 1 | | 84% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
| hyperbilirubinemia | 0.97 [0.48, 1.93] | | < 1 | | 0% | 2 studies (2/-) | 53.8 % | low | not evaluable | high | non important | - |
| long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| Major bleeding | 1.75 [1.14, 2.69] | | < 1 | | 0% | 4 studies (4/-) | 0.5 % | some concern | not evaluable | moderate | non important | - |
| pulmonary embolism | 0.82 [0.20, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| renal impairment | 1.26 [0.95, 1.67] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| severe adverse events | 1.10 [0.07, 18.09] | | < 1 | | 0% | 2 studies (2/-) | 47.4 % | high | not evaluable | low | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.96 [0.73, 1.27] | | < 1 | | 0% | 3 studies (3/-) | 60.5 % | some concern | not evaluable | moderate | non important | - |
